Hydroxyapatite/poly(epsilon-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery.

Hydroxyapatite (HA) porous scaffold was coated with HA and polycaprolactone (PCL) composites, and antibiotic drug tetracycline hydrochloride was entrapped within the coating layer. The HA scaffold obtained by a polymeric reticulate method, possessed high porosity ( approximately 87%) and controlled pore size (150-200 microm). Such a well-developed porous structure facilitated usage in a drug delivery system due to its high surface area and blood circulation efficiency. The PCL polymer, as a coating component, was used to improve the brittleness and low strength of the HA scaffold, as well to effectively entrap the drug. To improve the osteoconductivity and bioactivity of the coating layer, HA powder was hybridized with PCL solution to make the HA-PCL composite coating. With alteration in the coating concentration and HA/PCL ratio, the morphology, mechanical properties, and biodegradation behavior were investigated. Increasing the concentration rendered the stems thicker and some pores to be clogged; as well increasing the HA/PCL ratio made the coating surface be rough due to the large amount of HA particles. However, for all concentrations and compositions, uniform coatings were formed, i.e., with the HA particles being dispersed homogeneously in the PCL sheet. With the composite coating, the mechanical properties, such as compressive strength and elastic modulus were improved by several orders of magnitude. These improvements were more significant with thicker coatings, while little difference was observed with the HA/PCL ratio. The in vitro biodegradation of the composite coatings in the phosphate buffered saline solution increased linearly with incubation time and the rate differed with the coating concentration and the HA/PCL ratio; the higher concentration and HA amount caused the increased biodegradation. At short period (<2 h), about 20-30% drug was released especially due to free drug at the coating surface. However, the release rate was sustained for prolonged periods and was highly dependent on the degree of coating dissolution, suggesting the possibility of a controlled drug release in the porous scaffold with HA+PCL coating.

[1]  M. Sivakumar,et al.  Preparation, characterization and in vitro release of gentamicin from coralline hydroxyapatite-gelatin composite microspheres. , 2002, Biomaterials.

[2]  B. Lawn,et al.  Effect of Flaw State on the Strength of Brittle Coatings on Soft Substrates , 2004 .

[3]  J M Brady,et al.  Biodegradable ceramic implants in bone. Electron and light microscopic analysis. , 1971, Oral surgery, oral medicine, and oral pathology.

[4]  L G Griffith,et al.  Effect of pore size and void fraction on cellular adhesion, proliferation, and matrix deposition. , 2001, Tissue engineering.

[5]  John M. Powers,et al.  Hydroxyapatite fiber reinforced poly(α-hydroxy ester) foams for bone regeneration , 1998 .

[6]  R. Langer,et al.  Biodegradable polymers as drug delivery systems , 1990 .

[7]  Kemal Kesenci,et al.  Poly(d,l-cactide/ε-caprolactone)/hydroxyapatite composites , 2000 .

[8]  H. Uludaǧ,et al.  Growth Factor Delivery for Bone Tissue Engineering , 2001, Journal of drug targeting.

[9]  Mark Saltzman W,et al.  Materials for protein delivery in tissue engineering. , 1998, Advanced drug delivery reviews.

[10]  B. Lawn,et al.  Interfacial Layers in Brittle Cracks , 1988 .

[11]  N. Araki,et al.  Calcium hydroxyapatite ceramic used as a delivery system for antibiotics. , 1992, The Journal of bone and joint surgery. British volume.

[12]  H. Benghuzzi,et al.  Ceramic systems for long-term delivery of chemicals and biologicals. , 1988, Journal of biomedical materials research.

[13]  R. Holmes,et al.  Interporous hydroxyapatite as a bone graft substitute in tibial plateau fractures. , 1989, Clinical orthopaedics and related research.

[14]  W. Bonfield,et al.  Biodegradable drug delivery system for the treatment of bone infection and repair , 1999, Journal of materials science. Materials in medicine.

[15]  M. Braden,et al.  Novel hydroxyapatite-based dental composites. , 1994, Biomaterials.

[16]  V. Komlev,et al.  A method to fabricate porous spherical hydroxyapatite granules intended for time-controlled drug release. , 2002, Biomaterials.

[17]  C. G. Pitt Poly-ε-caprolactone and its copolymers , 1990 .

[18]  J. Sohier,et al.  A novel method to obtain protein release from porous polymer scaffolds: emulsion coating. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[19]  C. G. Pitt,et al.  The controlled parenteral delivery of polypeptides and proteins , 1990 .

[20]  Michael Jarcho,et al.  Calcium phosphate ceramics as hard tissue prosthetics. , 1981, Clinical orthopaedics and related research.

[21]  A. Krajewski,et al.  Porous ceramic bodies for drug delivery , 2000, Journal of materials science. Materials in medicine.

[22]  Hyoun‐Ee Kim,et al.  Porous ZrO2 bone scaffold coated with hydroxyapatite with fluorapatite intermediate layer. , 2003, Biomaterials.

[23]  Hyoun‐Ee Kim,et al.  Effect of CaF2 on densification and properties of hydroxyapatite-zirconia composites for biomedical applications. , 2002, Biomaterials.

[24]  S. Schwendeman,et al.  Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[25]  W. Bonfield,et al.  In vitro and in vivo evaluation of polyhydroxybutyrate and of polyhydroxybutyrate reinforced with hydroxyapatite. , 1991, Biomaterials.

[26]  M. Watanabe,et al.  Effect of blending calcium compounds on hydrolytic degradation of poly(DL-lactic acid-co-glycolic acid). , 2002, Biomaterials.

[27]  R. Holmes,et al.  Porous hydroxyapatite as a bone-graft substitute in metaphyseal defects. A histometric study. , 1986, The Journal of bone and joint surgery. American volume.

[28]  S F Hulbert,et al.  Potential of ceramic materials as permanently implantable skeletal prostheses. , 1970, Journal of biomedical materials research.

[29]  J Gillard,et al.  Preparation and characterization of protein-loaded poly(epsilon-caprolactone) microparticles for oral vaccine delivery. , 1999, International journal of pharmaceutics.

[30]  L L Hench,et al.  Surface-active biomaterials. , 1984, Science.

[31]  A. Elfick Poly(ε-caprolactone) as a potential material for a temporary joint spacer , 2002 .

[32]  P. Taddei,et al.  Spectroscopic study on the in vitro degradation of a biodegradable composite periodontal membrane , 2001 .